Bioverge Fills an Early-Stage Funding Gap While Democratizing Private Investing

article image

Investment portal Bioverge offers a new source of capital for seeding healthcare companies that have disruptive ideas. At the same time, its equity crowdfunding model is able to engage individual investors that have never before had the opportunity to invest in private companies.

Start-ups developing disruptive healthcare solutions almost inevitably have to pass through the proverbial “Valley of Death,” the journey that begins after a company is founded with a bit of funding from the NIH or other grantors, through the milestones of seed funding and the Series A round to more sustainability. Fledgling companies have a tough time here, and many don’t make it out. Investors generally regard unprecedented solutions as too risky, even when the problems start-ups are trying to solve are universally recognized as big ones.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: